Gossamer Bio, Inc.

When even the sellside describes a biotech’s sole product as “an abject failure”, the company is clearly in trouble. Aerovate Therapeutics, Inc ’s value was shredded yesterday after it canned its pul

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip 's global team, in this podcast version of Five Must-Know Things. This ep

Gossamer Bio, Inc. is testing its inhaled kinase inhibitor seralutinib in a Phase III clinical trial as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH), but has its

Last month, Merck & Co., Inc. ’s Winrevair (sotatercept) became the first disease-modifying therapy approved for pulmonary arterial hypertension (PAH) and expectations for the product are high, with